- Home
- HRMY vs AMSC Comparison
HRMY vs AMSC Comparison
Compare HRMY & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | AMSC |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | 400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | HRMY | AMSC |
|---|---|---|
| Price | $29.34 | $39.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $46.70 | ★ $52.00 |
| AVG Volume (30 Days) | 605.9K | ★ 869.1K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 143.24 |
| EPS | 2.71 | ★ 3.01 |
| Revenue | ★ $868,453,000.00 | $900,000.00 |
| Revenue This Year | $19.75 | $34.98 |
| Revenue Next Year | $12.88 | $21.38 |
| P/E Ratio | ★ $10.72 | $12.56 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $17.16 |
| 52 Week High | $40.87 | $70.49 |
Technical Indicators
Market Signals| Indicator | HRMY | AMSC |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 68.41 |
| Support Level | $25.92 | $38.80 |
| Resistance Level | $30.96 | $64.57 |
| Average True Range (ATR) | 0.82 | 2.12 |
| MACD | 0.42 | 0.75 |
| Stochastic Oscillator | 91.72 | 99.65 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.